DPP4 and type 2 diabetes mellitus: In T2DM patients already presenting with CVD, principally all drugs (DPP-4 inhibitors, GLP-1 receptor agonists, and basal insulin glargine) with confirmed safety in outcome studies [16–20] could be used, however in order to reduce CV events and CV death, a combination of drugs should be preferred with documented CV benefit.